Pasar al contenido principal

ACTIVIDADES NO CONVENCIONALES DEL MEDIADOR AUTOFAGICO ATG16L1 Y SU RELEVANCIA EN FISIOLOGIA Y PATOLOGIA

PID2020-114699RB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

ATG16L1 WD40 domain-dependent IL10R (interleukin 10 receptor) signaling is insensitive to the T300A Crohn disease risk polymorphism

  • Serramito-Gómez, Inmaculada
  • Terraza-Silvestre, Elena
  • Fernández-Cabrera, Álvaro
  • Villamuera, Raquel
  • Pimentel-Muiños, Felipe X.
A coding allele of ATG16L1 that increases the risk of Crohn disease (T300A; rs2241880) impairs the interaction between the C-terminal WD40 domain (WDD) and proteins containing a WDD-binding motif, thus specifically inhibiting the unconventional autophagic activities of ATG16L1. In a recent publication we described a novel atypical role of ATG16L1 in the regulation of IL10R (interleukin 10 receptor) trafficking and signaling, an activity that involves direct interaction between the WDD and a target motif present in IL10RB (interleukin 10 receptor subunit beta). Here we show that, unexpectedly, neither the ability of ATG16L1 to interact with IL10RB nor its role in supporting IL10 signaling are altered by the T300A mutation. These results indicate that the ATG16L1T300A allele selectively impairs the interaction between the WDD and a subset of WDD-binding motif versions, suggesting that only a fraction of the unconventional activities mediated by ATG16L1 are required to prevent Crohn disease., This work was supported by the Ministerio de Economía, Industria y Competitividad, Gobierno de España [SAF2017-88390-R, PID2020-114699RB-100]; Consejería de Educación, Junta de Castilla y León [SA042P17] and [CLC-2017-01]; Crohn’s and Colitis Foundation of America [IBD-0369]; Fundación Solórzano (USAL) [FS/18-2014]”, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

An unconventional autophagic pathway that inhibits ATP secretion during apoptotic cell death

  • Terraza-Silvestre, Elena
  • Villamuera, Raquel
  • Bandera-Linero, Julia
  • Letek, Michal
  • Oña-Sánchez, Daniel
  • Ramón-Barros, Cristina
  • Moyano-Jimeno, Clara
  • Pimentel-Muiños, Felipe X.
Mobilisation of Damage-Associated Molecular Patterns (DAMPs) determines the immunogenic properties of apoptosis, but the mechanisms that control DAMP exposure are still unclear. Here we describe an unconventional autophagic pathway that inhibits the release of ATP, a critical DAMP in immunogenic apoptosis, from dying cells. Mitochondrial BAK activated by BH3-only molecules interacts with prohibitins and stomatin-1 through its latch domain, indicating the existence of an interactome specifically assembled by unfolded BAK. This complex engages the WD40 domain of the autophagic effector ATG16L1 to induce unconventional autophagy, and the resulting LC3-positive vesicles contain ATP. Functional interference with the pathway increases ATP release during cell death, reduces ATP levels remaining in the apoptotic bodies, and improves phagocyte activation. These results reveal that an unconventional component of the autophagic burst that often accompanies apoptosis sequesters intracellular ATP to prevent its release, thus favouring the immunosilent nature of apoptotic cell death., This work was funded by grants SAF2017-88390-R (F.X.P), PID2020-114699RB-I00 (F.X.P) and PID2023-148747OB-I00 (F.X.P) from the Ministerio de Ciencia y Tecnología (Spanish Government; MCIN/AEI/10.13039/501100011033, FEDER, UE), IDEAS18093PIME from the Asociación Española Contra el Cáncer (AECC) and SA042P17 from the Junta de Castilla y León local government. Additional funding comes from the Excellence Severo Ochoa Grant CEX2021-001154-S from MCIN/AEI/10.13039/501100011033. The CBM receives institutional support by Fundación Ramon Areces. E.T. and J.B.L. are recipients of predoctoral fellowships PRE2018-085243 and PRE2021-097461, respectively, from the Formación de Personal Investigador (FPI) programme of the Spanish Ministry of Science and Technology (MCIU/AEI/10.13039/501100011033; Spanish Government and FSE + ). F.X.P. holds a tenured position at CSIC.